With nations around the world gearing up to prepare for an outbreak of bird flu, investors should consider adding Western bio-technology companies with profit potential and strong research and development capabilities to their portfolios.
"Although avian flu has become a hot issue recently, investors should still examine companies' future potential and drug manufacturing capabilities, instead of just checking their price-to-earnings ratios," said Mark Fu (
Fu manages biotech and pharmaceutical funds worth NT$8 billion (US$238 million).
Addressing a seminar organized by the publisher Wealth Group (財訊) yesterday, Fu said that in contrast with the 2003 SARS outbreak, when no cure was available, the drug Tamiflu has been proven effective in relieving the symptoms of avian flu, thereby creating a massive business opportunity for biotech shares.
US biotech firm Gilead, which developed Tamiflu but signed a development and licensing agreement with Swiss pharmaceutical company Roche nine years ago, remains a major beneficiary as it is entitled to royalties of between 7 percent and 14 percent from Roche.
For every US$1 billion of Tamiflu sold, Gilead can pocket US$100 million of royalties, Fu said, adding that the US firm's earnings per share (EPS) for next year is expected to jump 8 percent, or US$0.14.
Roche, which sold US$300 million of Tamiflu last year, is projected to report skyrocketing sales in the anti-bird flu drug this year, to US$1 billion, rising to US$1.2 billion next year.
Per-share earnings next year are forecast to climb by 7 percent, Fu said.
Share prices of these two companies, along with British drug maker GlaxoSmithKline, which manufactures the Relenza inhaler, have reached new highs this year, with analysts also upgrading their ratings on the firms.
In addition, as the fourth quarter is the biotech sector's traditional peak season when major medical conferences are held, releasing the latest company reports, Fu said interested investors should watch closely and adjust their portfolios accordingly.
"Taiwan should be able to see biotech companies emerging" to become favorable investment targets, he said.
Hsieh Chin-ho (
Nvidia Corp’s demand for advanced packaging from Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) remains strong though the kind of technology it needs is changing, Nvidia CEO Jensen Huang (黃仁勳) said yesterday, after he was asked whether the company was cutting orders. Nvidia’s most advanced artificial intelligence (AI) chip, Blackwell, consists of multiple chips glued together using a complex chip-on-wafer-on-substrate (CoWoS) advanced packaging technology offered by TSMC, Nvidia’s main contract chipmaker. “As we move into Blackwell, we will use largely CoWoS-L. Of course, we’re still manufacturing Hopper, and Hopper will use CowoS-S. We will also transition the CoWoS-S capacity to CoWos-L,” Huang said
Nvidia Corp CEO Jensen Huang (黃仁勳) is expected to miss the inauguration of US president-elect Donald Trump on Monday, bucking a trend among high-profile US technology leaders. Huang is visiting East Asia this week, as he typically does around the time of the Lunar New Year, a person familiar with the situation said. He has never previously attended a US presidential inauguration, said the person, who asked not to be identified, because the plans have not been announced. That makes Nvidia an exception among the most valuable technology companies, most of which are sending cofounders or CEOs to the event. That includes
TARIFF TRADE-OFF: Machinery exports to China dropped after Beijing ended its tariff reductions in June, while potential new tariffs fueled ‘front-loaded’ orders to the US The nation’s machinery exports to the US amounted to US$7.19 billion last year, surpassing the US$6.86 billion to China to become the largest export destination for the local machinery industry, the Taiwan Association of Machinery Industry (TAMI, 台灣機械公會) said in a report on Jan. 10. It came as some manufacturers brought forward or “front-loaded” US-bound shipments as required by customers ahead of potential tariffs imposed by the new US administration, the association said. During his campaign, US president-elect Donald Trump threatened tariffs of as high as 60 percent on Chinese goods and 10 percent to 20 percent on imports from other countries.
INDUSTRY LEADER: TSMC aims to continue outperforming the industry’s growth and makes 2025 another strong growth year, chairman and CEO C.C. Wei says Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), a major chip supplier to Nvidia Corp and Apple Inc, yesterday said it aims to grow revenue by about 25 percent this year, driven by robust demand for artificial intelligence (AI) chips. That means TSMC would continue to outpace the foundry industry’s 10 percent annual growth this year based on the chipmaker’s estimate. The chipmaker expects revenue from AI-related chips to double this year, extending a three-fold increase last year. The growth would quicken over the next five years at a compound annual growth rate of 45 percent, fueled by strong demand for the high-performance computing
RSS